Introduction
============

Atherosclerosis is a systemic, multifocal disease that represents the leading cause of death in Western countries.^[@bib1]^ The risk factors contributing to its distribution, extent and progression in different organs (i.e., the heart, brain or limbs) and different segments (large and small vessels) are not identical.^[@bib2],\ [@bib3],\ [@bib4]^ In particular, smoking and diabetes mellitus seem to be more strictly associated with lower limb atherosclerosis (termed peripheral arterial disease (PAD)), with respect to coronary heart and cerebrovascular districts, independently of the severity of the underlying atherosclerosis.^[@bib5]^ Moreover, there are striking dissimilarities between the arterial regions of the lower extremities: smoking and hypercholesterolemia are closely related to the involvement of the iliac and femoropopliteal (proximal) district, whereas diabetes mellitus is closely related to the involvement of the infrageniculate (distal) district.^[@bib6]^

The findings relating to the distribution pattern of peripheral atherosclerotic lesions generally have been obtained from studies of patients undergoing surgical or endovascular treatment for advanced stages of PAD (generally Fontaine stages III--IV), which correspond to the detection of hemodynamically significant lesions through instrumental imaging. Moreover, the diagnostic techniques used in these studies are typically limited to angiography or ankle--brachial index (ABI) evaluation, which are two methods that do not provide information about early atherosclerotic lesions and about the entire atherosclerotic burden. In medicine, there is an increased need to identify early lesions, which act as markers of vascular damage associated with increased cardiovascular (CV) risk; thus, searching only for signs of advanced PAD that can result in superficial findings. These considerations are relevant considering the recent involvement of PAD in CV risk stratification. In recent years, several imaging techniques, including ultrasonography, have been suggested to distinctly evaluate the entire arterial tree of the lower limbs, enabling atherosclerotic lesions to be identified at all disease stages.

Currently, no data evaluating the association between traditional CV risk factors and PAD consider all stages of PAD, including early atherosclerotic lesions.

Therefore, the aims of this study are (i) to propose a new ultrasonographic score, the ULLA (ultrasonographic lower limb atherosclerosis) score, which categorizes atherosclerotic lesions of the lower limbs at all stages of PAD, and (ii) to associate these ultrasonographic categories with CV risk profiles.

Patients and Methods
====================

Patients
--------

All consecutive subjects with symptoms suggestive of PAD or with known CV risk factors who were referred to our angiology unit between 1 July 2014 and 30 June 2015 for ultrasonographic evaluation of the lower limb arteries were recruited for the study. The exclusion criterion was age \<18 years.

CV risk factors included in the statistical model were age, gender, diabetes mellitus status, arterial hypertension status, dyslipidemia status, body mass index (BMI), cigarette smoking modeled as both number (packs per year) and smoking status ('never', 'former' and 'active'), sedentary lifestyle, previous CV events and family history of CV disease. The presence of diabetes mellitus status was determined based on the following indicators: fasting plasma glucose concentration (after 8 or more hours of no caloric intake) ⩾126 mg dl^−1^; plasma glucose concentration ⩾200 mg dl^−1^ 2 h after ingesting a 75 g oral glucose load in the morning after an overnight fast of at least 8 h; symptoms of hyperglycemia (e.g., polyuria, polydipsia, polyphagia) and a random (casual, non-fasting) plasma glucose concentration ⩾200 mg dl^−1^; or hemoglobin A1c level ⩾6.5%.^[@bib7]^ The presence of arterial hypertension status was defined by systolic blood pressure \>140 mm Hg and/or diastolic blood pressure \>90 mm Hg or in case of consumption of any antihypertensive drug.^[@bib8]^ The presence of dyslipidemia status was defined by low-density lipoprotein cholesterol level \>130 mg dl^−1^, total cholesterol level \>200 mg dl^−1^, triglyceride level \>150 mg dl^−1^, high-density lipoprotein cholesterol level \<50 mg dl^−1^ or in case of consumption of any lipid-lowering drug.^[@bib9]^

Ultrasound lower limb evaluation
--------------------------------

Ultrasonographic examination was performed using a high-resolution Philips iU22 sonograph (Philips Medical Systems, Monza, Italy) and a linear 9--3 MHz transducer. Patients were placed in a supine position; the femoropopliteal and run-off segments were continuously scanned from the subinguinal region to the paramalleolar region with axial and sagittal scans. All segments were examined for their parietal characteristics, especially the presence of vessel wall calcifications and/or atherosclerotic plaques. In addition, flow velocity measurements were obtained using spectral Doppler imaging with an insonation angle of 60° and color Doppler imaging. Arteries were grouped into femoropopliteal or proximal (common, superficial and deep femoral arteries, popliteal artery) and infrageniculate or distal (tibiofibular trunk, anterior and posterior tibial arteries, fibular artery) districts.

A new ultrasonographic, semiquantitative scoring system for disease severity assessment, the ULLA score, was proposed for assessing the proximal and distal districts. The lesions in the proximal district were categorized into six groups: (I) normal parietal characteristics (no vessel wall calcifications and/or atherosclerotic plaques), with normal flow velocity measurements; (II) presence of non-stenotic parietal calcifications, with normal flow velocity measurements; (III) presence of atherosclerotic plaques stenosing the artery by not \>30%, with normal flow velocity measurements; (IV) presence of stenosing atherosclerotic plaques narrowing the lumen \>30% but \<70%, with normal flow velocity measurements; (V) presence of stenosing atherosclerotic plaques narrowing the lumen \>70%, with alteration of flow velocity measurements; and (VI) complete occlusion of the lumen.

The lesions in the distal district were categorized into five groups: (I) normal parietal characteristics (no vessel wall calcifications and/or atherosclerotic plaques), with normal flow velocity measurements; (II) presence of non-stenotic parietal calcifications, with normal flow velocity measurements; (III) presence of non-stenotic atherosclerosis, with normal flow velocity measurements; (IV) presence of atherosclerosis, with alteration of flow velocity measurements; and (V) complete occlusion of the lumen. Non-stenotic distal district lesions characterized by normal flow velocity measurements were grouped together because of the reduced accuracy of this tool when making precise stenoses evaluations in small vessels and in cases of poor clinical significance.

All scans were performed by the same experienced vascular sonographer.

Statistical analysis
--------------------

Between-group differences were assessed using an analysis of variance for normally distributed continuous variables, the Kruskal--Wallis test for non-normally distributed continuous variables and a *χ*^2^ test for nominal variables. The ULLA total severity score was defined as the highest of the proximal or distal scores, regardless of the involvement of one or both legs; moreover, the proximal and distal scores were evaluated separately.

Associations between each CV risk factor and the ULLA scores were assessed with ordered logistic models. Models were further adjusted for age, gender and BMI, and the univariate and adjusted estimates of association are presented. The full set of analyses was repeated after the exclusion of participants with altered ABI (i.e., ABI\<0.9). All statistical analyses were performed with Stata MP 13.0 (StataCorp, College Station, TX, USA). A two-tailed *P*-value \<0.05 was regarded as statistically significant.

Ethical approval
----------------

Written informed consent was obtained from all participants before their enrollment in the study. The study was performed in accordance with the Declaration of Helsinki and was approved by the ethics committee of the Catholic University of Rome (ethics committee reference number: 14725/2014).

Results
=======

Overall, 320 participants were included in the study; their baseline characteristics by total severity score are reported in [Table 1](#tbl1){ref-type="table"}.

Univariate and multivariate estimates of the association between CV risk factors and ULLA scores (total severity score and proximal and distal districts scores) are reported in [Table 2](#tbl2){ref-type="table"}.

In the univariate analyses, all the ULLA scores were significantly associated with age and male gender, but not with BMI. After adjusting for age, gender and BMI, there was a statistically significant association between the total severity score and pack-years of smoking (*P*\<0.001), smoking status (*P*\<0.001), arterial hypertension (*P*=0.001), diabetes (*P*=0.004), dyslipidemia (*P*=0.04), sedentary lifestyle (*P*=0.02) and previous CV events (*P*=0.01); the association with family history of CV disease was marginally significant (*P*=0.05). When the proximal and distal districts were considered separately, smoking status (*P*=0.01) and dyslipidemia (*P*=0.02) were selectively associated with the proximal district score, whereas family history of CV disease (*P*=0.03) and sedentary lifestyle (*P*=0.002) were selectively associated with the distal district score. Packs per year of smoking, arterial hypertension and diabetes were significantly associated with both proximal and distal district scores. However, for arterial hypertension, the magnitude of the association was larger for the proximal district score (odds ratio (OR) 2.26 *vs.* 1.90), whereas for diabetes it was larger for the distal district score (OR 2.41 *vs.* 1.75).

After excluding those participants with altered ABI (*n*=79) or PAD symptoms (*n*=39) from the analysis, the results remained substantially unaltered, except for previous CV events, which was no longer associated with the scores of subjects with normal ABI ([Tables 3](#tbl3){ref-type="table"} and [4](#tbl4){ref-type="table"}).

Discussion
==========

Most studies of atherosclerosis identify patients as affected by PAD only if they report symptoms suggestive of PAD or provide instrumental demonstration of lower limb perfusion deficits. This trend may explain why PAD remains, probably, the most underdiagnosed and least aggressively managed atherosclerotic disease. However, several studies have indicated that patients with PAD have an increased risk for all-cause mortality and for death from coronary heart disease than those without PAD.^[@bib10],\ [@bib11],\ [@bib12]^ It is important to address the presence of atherosclerotic lesions in the lower limb districts before they become apparent as a clinical PAD syndrome. Currently, the presence of subclinical vascular damage represents a topic of great interest; examples include the pivotal role of carotid intima--media thickness in stratifying patients who are candidates for therapy initiation and the role of arterial stiffness in predicting future CV events in patients with coronary artery disease.^[@bib13],\ [@bib14],\ [@bib15]^

The lack of an adequate evaluation of early atherosclerotic lesions of the lower limbs is a serious shortcoming, especially when considering the possible association of PAD with known CV risk factors and the possible predictive role of PAD and its involvement in global CV risk stratification.

To overcome these limits, in this study, we introduced a new ultrasonographic score, the ULLA score, which facilitates the categorization of atherosclerotic lesions of the lower limbs in all stages of PAD and associating these ultrasonographic categories with CV risk profiles. The main finding of our study is that the total severity index of the proposed ultrasonographic score is associated with age and male gender and with the other main traditional CV risk factors, that is, smoking, hypertension, diabetes, dyslipidemia, sedentary lifestyle and previous CV events, even after adjustment for age, gender and BMI. Moreover, our data confirm that specific CV risk factors are selectively associated with the proximal or distal districts; in particular, smoking status and dyslipidemia are selectively associated with the proximal district score, whereas CV family history and sedentary lifestyle are selectively associated with the distal district score. Packs per year of smoking, hypertension and diabetes are significantly associated with both the proximal and distal district scores. However, for hypertension, the magnitude of the association is larger for the proximal district score, whereas for diabetes it is larger for the distal district score. Numerous hypotheses have been proposed to explain the site selectivity of atherosclerotic lesions, including hemodynamic stress related to arterial geometry and anatomic, cellular or biochemical variations in the arterial wall.^[@bib16]^

These findings confirm what is already known about the correlation between PAD and CV risk factors and with regard to specific districts and single CV risk factors. The findings extend the relationships established in previous studies to all stages of PAD, including early, asymptomatic stages. The current data, in fact, generally have been obtained from studies of patients undergoing endovascular treatment for advanced stages of PAD (generally Fontaine stages III--IV), which correspond to the detection of hemodynamically significant lesions through instrumental imaging. Moreover, the diagnostic tool used in most studies has been angiography, which is considered the gold standard for grading atherosclerotic lesions of the lower extremities.^[@bib17]^ Nonetheless, some limitations for this technique must be considered. First, angiography only allows the specific study of the proximal arteries, with segments distal to the popliteal artery often not considered because of their relatively poor visualization. Moreover, in many angiographic studies, disease severity was based on the number of occlusions, and the atherosclerotic pattern was defined only by the endovascular target lesions treated.^[@bib18]^ Finally, in several studies, subjects with stenosis that did not reach 50% in any of the segments of the lower limb arterial tree were excluded.^[@bib19]^ Consequently, angiography does not provide information about early atherosclerotic lesions, and the entire atherosclerotic burden is often not considered for analysis.

Other studies have used noninvasive techniques to assess PAD by detecting perfusion effects rather than the degree or site of stenosis within single arteries. Most of these include ABI evaluation, a measurement comparing the ankle systolic blood pressure to the brachial artery systolic blood pressure. This test is simple, noninvasive, risk free and inexpensive, and with an ABI value \<0.90 indicative of PAD, it has acceptable diagnostic performance properties for PAD screening (sensitivity 79--95% specificity 95--100%).^[@bib20],\ [@bib21]^ However, ABI results are abnormal only in the presence of advanced arterial lesions able to reduce ankle systolic blood pressure; therefore, early atherosclerotic lesions of the lower limbs cannot be detected by ABI measurement. Moreover, ABI could produce 'pseudonormal' values in the presence of arterial stiffening; thus, ABI is an imperfect marker of lower limb perfusion, especially in diabetic patients.^[@bib22]^

As mentioned above, the proposed ULLA score overcomes these limitations, allowing a complete evaluation of the entire lower limb atherosclerotic burden and extending the results to all stages of PAD, including early stages. Moreover, after excluding patients with altered ABI or with symptoms suggestive of PAD, our results remained substantially unchanged, confirming the robustness of the proposed score even in the early, preclinical stages of PAD. This result is especially important when we consider that only 10% of patients affected by PAD have the classic symptoms of intermittent claudication; most patients report atypical symptoms or no symptoms at all.^[@bib23]^ The only reported difference is represented by the loss of association between previous CV events and ULLA scores in the 241 patients with normal ABI, even after adjusting for age and the other traditional CV risk factors. It is plausible that this result reflects the reduced systemic involvement of vascular damage in these patients.

Considering PAD at all stages of the disease can have a role also in the recent research revealing the role of PAD involvement in CV risk stratification. Risk stratification in CV disease prevention represents a major goal for twenty-first century medicine. Assessment of traditional CV risk factors, such as blood pressure and low-density lipoprotein cholesterol levels, remains the cornerstone of risk estimation; however, a residual risk may remain even after controlling for traditional CV risk factors. Therefore, new markers, mainly those related to inflammation and genetic profiles, have recently been added to scoring systems to better assess the risk of CV disease, together with instrumental techniques for measuring asymptomatic organ damage.^[@bib24],\ [@bib25]^ Among these instrumental techniques, those techniques that evaluate the cardiac and carotid districts seem to be the most effective. In particular, the independent prognostic value of carotid ultrasonography with evaluation of carotid intima--media thickness and plaques in predicting CV events has been widely demonstrated.^[@bib26],\ [@bib27],\ [@bib28]^ Recently, the presence of PAD has also been considered in the assessment of organ damage to better define the existing CV risk profile. Patients affected by ABI-assessed PAD have higher CV mortality and morbidity than age-matched controls without PAD, even after adjusting for traditional CV risk factors using the Framingham Risk Score, and these findings are similar for individuals with symptomatic and asymptomatic PAD.^[@bib10],\ [@bib11],\ [@bib12]^ Studies involving ultrasound evaluation of the lower limb districts have shown the femoral intima--media thickness measurement to be an indicator of symptomatic coronary atherosclerosis.^[@bib29],\ [@bib30],\ [@bib31],\ [@bib32]^

The proposed ULLA score for PAD, which is able to categorize earlier stages of the disease, could change the predictive value of PAD in assessing CV risk. In particular, our findings could improve the identification of individuals with a low-moderate 10-year risk for CV disease based on classical scoring systems but a moderate-high lifetime risk, allowing these individuals to benefit from early interventions designed to prevent progression to the high-risk group in later life. Moreover, exploring the possible presence of subclinical atherosclerosis in the lower limb districts could be of interest because multiple organ damage carries a worse prognosis than single organ involvement.^[@bib33],\ [@bib34]^ In individuals with one or more classical risk factors who do not appear to have a high total CV risk according to current methods of quantification, subclinical organ damage is common. The Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm demonstrated that treatment of patients with indicators of subclinical CV disease could reduce CV events.^[@bib35]^

Another important implication of the ULLA score is the ability to compare the real association of CV risk factors with the atherosclerotic lesion distribution in different districts. This association is often deduced through instrumental methods with different sensitivities.^[@bib36]^ Moreover, a complete tool for identifying PAD stages in all patients is fundamental for the assessment of PAD progression; currently, most studies conducted for this purpose have used only ABI or angiographic evaluation, establishing that smoking and diabetes mellitus are the most important factors in PAD progression.^[@bib37],\ [@bib38]^ The use of a more appropriate instrumental technique that is more accurate, especially in identifying early lesions, could also facilitate the association of PAD with novel biomarkers of the atherosclerosis process associated with pathways of inflammation, lipoprotein and adipocyte metabolism, hemodynamic stress, calcification and hemostasis.^[@bib39],\ [@bib40]^

Certainly, the most interesting future research on the proposed ULLA score will be studying its predictive properties with respect to the risk of CV event development. In fact, it is well known that only a small percentage of patients with PAD require lower extremity intervention; thus, screening for PAD should be not beneficial as much in reducing the risk of symptomatic PAD or ischemic limb event, rather than it should be help identify those who need aggressive preventive measures for CV and cerebrovascular risk reduction.

The authors declare no conflict of interest.

###### Baseline characteristics of the study population by ULLA total severity score

                                  *Total severity score*                                                                    
  ------------------------------ ------------------------ ------------ ------------ ------------ ------------ ------------- ---------
  *N*                                       36                 86           89           27           63           19        
  Age, mean (s.d.)                       59 (10)            69 (10)       69 (9)       72 (7)       74 (8)       74 (8)     \<0.001
                                                                                                                             
  Gender                                                                                                                    \<0.001
   F                                     29 (81%)           62 (72%)     49 (55%)     9 (33%)      22 (35%)      3 (16%)     
   M                                     7 (19%)            24 (28%)     40 (45%)     18 (67%)     41 (65%)     16 (84%)     
  Altered ABI                             2 (6%)             7 (8%)      10 (11%)     7 (26%)      34 (54%)     19 (100%)   \<0.001
  BMI, mean (s.d.)                      27.2 (5.1)         27.3 (3.9)   27.7 (4.9)   28.9 (4.9)   26.1 (3.5)   25.8 (2.9)   0.043
  Packs per year, median (IQR)          3 (0, 11)           0 (0, 8)    15 (0, 30)   11 (0, 36)   23 (0, 38)   45 (18, 60)  \<0.001
                                                                                                                             
  Smoking status                                                                                                            \<0.001
   Never                                 13 (36%)           55 (64%)     32 (36%)     9 (33%)      16 (25%)      2 (11%)     
   Former                                14 (39%)           21 (24%)     40 (45%)     14 (52%)     35 (56%)     12 (63%)     
   Active                                9 (25%)            10 (12%)     17 (19%)     4 (15%)      12 (19%)      5 (26%)     
  Hypertension                           15 (42%)           53 (62%)     65 (73%)     19 (70%)     55 (87%)     15 (79%)    \<0.001
  Diabetes                                3 (8%)            24 (28%)     26 (29%)     15 (56%)     31 (49%)      6 (32%)    \<0.001
  Dyslipidemia                           17 (47%)           49 (57%)     60 (67%)     16 (59%)     39 (62%)     12 (63%)    0.42
  CV family history                      28 (78%)           67 (78%)     75 (84%)     16 (59%)     50 (79%)     16 (84%)    0.15
  Sedentary lifestyle                    5 (14%)            18 (21%)     27 (30%)     5 (19%)      26 (41%)      5 (26%)    0.025
  CV events                               3 (8%)            12 (14%)     19 (21%)     8 (30%)      24 (38%)     10 (53%)    \<0.001

Abbreviations: ABI, ankle--brachial index; BMI, body mass index; CV, cardiovascular; ULLA, ultrasonographic lower limbs atherosclerosis.

###### Associations between risk factors and ULLA scores

                                                *Total severity*        *Proximal*      *Distal*                                                    
  --------------------------------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  Age (1 year)                                  1.08 (1.06, 1.10)           ---         1.07 (1.05, 1.09)           ---         1.10 (1.08, 1.13)           ---
  Male gender                                   4.17 (2.74, 6.34)           ---         3.99 (2.61, 6.09)           ---         3.21 (2.10, 4.93)           ---
  BMI[a](#t2-fn2){ref-type="fn"} (1 kg m^−2^)   0.97 (0.93, 1.02)           ---         0.97 (0.93, 1.02)           ---         0.97 (0.92, 1.02)           ---
  Packs per year (1U)                           1.03 (1.02, 1.04)    1.02 (1.02, 1.03)  1.03 (1.02, 1.04)    1.03 (1.02, 1.04)  1.02 (1.01, 1.03)    1.02 (1.01, 1.03)
                                                                                                                                                              
  *Smoking status*[b](#t2-fn3){ref-type="fn"}                                                                                                                 
   Former                                       2.73 (1.76, 4.25)    1.62 (0.95, 2.78)  2.71 (1.74, 4.22)    1.61 (0.94, 2.75)  1.87 (1.19, 2.92)    1.14 (0.65, 2.00)
   Active                                       1.94 (1.10, 3.44)    2.65 (1.40, 5.01)  2.10 (1.17, 3.76)    2.77 (1.45, 5.29)  1.03 (0.57, 1.87)    1.58 (0.81, 3.11)
  Hypertension                                  2.91 (1.87, 4.53)    2.23 (1.40, 3.57)  2.96 (1.90, 4.63)    2.26 (1.41, 3.63)  2.65 (1.68, 4.18)    1.90 (1.17, 3.10)
  Diabetes                                      2.36 (1.55, 3.58)    1.94 (1.24, 3.02)  2.13 (1.40, 3.25)    1.75 (1.12, 2.73)  2.71 (1.75, 4.20)    2.41 (1.50, 3.87)
  Dyslipidemia                                  1.34 (0.90, 2.00)    1.52 (1.01, 2.30)  1.48 (0.99, 2.22)    1.62 (1.08, 2.45)  1.04 (0.69, 1.57)    1.05 (0.68, 1.61)
  CV family history                             1.00 (0.62, 1.61)    1.63 (0.99, 2.67)  0.94 (0.59, 1.52)    1.38 (0.85, 2.26)  0.96 (0.59, 1.57)    1.76 (1.04, 2.96)
  Sedentary                                     1.82 (1.18, 2.83)    1.77 (1.12, 2.81)  1.41 (0.91, 2.19)    1.30 (0.82, 2.07)  2.26 (1.42, 3.58)    2.21 (1.34, 3.64)
  CV events                                     3.33 (2.07, 5.36)    1.95 (1.17, 3.23)  3.69 (2.28, 5.99)    2.22 (1.33, 3.72)  2.98 (1.83, 4.83)    1.77 (1.04, 3.00)

Abbreviations: BMI, body mass index; CV, cardiovascular; OR, odds ratio; ULLA, ultrasonographic lower limbs atherosclerosis.

Multivariate models adjusted for age, gender and BMI.

Reference group, never smoked.

###### Associations between risk factors and ULLA scores among participants with normal ABI

                                                *Total severity*        *Proximal*      *Distal*                                                    
  --------------------------------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  Age (1 year)                                  1.08 (1.05, 1.11)           ---         1.08 (1.05, 1.11)           ---         1.11 (1.07, 1.14)           ---
  Male gender                                   3.16 (1.94, 5.15)           ---         2.93 (1.78, 4.80)           ---         2.72 (1.63, 4.54)           ---
  BMI[a](#t3-fn2){ref-type="fn"} (1 kg m^−2^)   1.02 (0.97, 1.07)           ---         1.02 (0.96, 1.07)           ---         1.02 (0.97, 1.08)           ---
  Packs per year (1 U)                          1.02 (1.01, 1.04)    1.03 (1.01, 1.04)  1.02 (1.01, 1.04)    1.02 (1.01, 1.04)  1.01 (1.00, 1.02)    1.02 (1.00, 1.03)
                                                                                                                                                    
  *Smoking status*[b](#t3-fn3){ref-type="fn"}                                                                                                       
   Former                                       2.14 (1.28, 3.58)    1.49 (0.81, 2.76)  1.92 (1.15, 3.22)    1.31 (0.72, 2.41)  1.67 (0.98, 2.84)    1.18 (0.62, 2.24)
   Active                                       1.17 (0.61, 2.25)    1.95 (0.96, 3.97)  1.15 (0.59, 2.23)    1.80 (0.87, 3.70)  0.58 (0.29, 1.17)    1.09 (0.50, 2.37)
  Hypertension                                  2.78 (1.68, 4.60)    2.17 (1.26, 3.75)  3.03 (1.82, 5.04)    2.35 (1.34, 4.10)  2.37 (1.39, 4.03)    1.61 (0.90, 2.87)
  Diabetes                                      2.57 (1.55, 4.26)    2.32 (1.35, 3.99)  2.19 (1.31, 3.66)    1.95 (1.12, 3.39)  2.97 (1.74, 5.07)    2.75 (1.54, 4.90)
  Dyslipidemia                                  1.63 (1.01, 2.63)    1.66 (1.01, 2.71)  1.86 (1.15, 3.01)    1.85 (1.13, 3.04)  1.17 (0.71, 1.93)    1.06 (0.63, 1.78)
  CV family history                             1.15 (0.65, 2.05)    1.94 (1.07, 3.53)  0.92 (0.51, 1.64)    1.30 (0.72, 2.38)  1.15 (0.63, 2.11)    2.13 (1.12, 4.05)
  Sedentary                                     2.13 (1.27, 3.57)    1.84 (1.06, 3.17)  1.55 (0.93, 2.59)    1.23 (0.71, 2.12)  2.31 (1.34, 4.00)    1.94 (1.07, 3.51)
  CV events                                     2.06 (1.14, 3.71)    1.12 (0.59, 2.12)  2.41 (1.30, 4.48)    1.37 (0.71, 2.66)  1.84 (0.99, 3.41)    1.03 (0.52, 2.02)

Abbreviations: ABI, ankle--brachial index; BMI, body mass index; CV, cardiovascular; OR, odds ratio; ULLA, ultrasonographic lower limbs atherosclerosis.

Multivariate models adjusted for age, gender and BMI.

Reference group, never smoked.

###### Associations between risk factors and ULLA scores among participants with no symptoms

                                                *Total severity*        *Proximal*      *Distal*                                                    
  --------------------------------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  Age (1 year)                                  1.08 (1.05, 1.10)           ---         1.07 (1.05, 1.10)           ---         1.11 (1.08, 1.13)           ---
  Male gender                                   3.72 (2.37, 5.83)           ---         3.92 (2.48, 6.20)           ---         3.06 (1.92, 4.88)           ---
  BMI[a](#t4-fn2){ref-type="fn"} (1 kg m^−2^)   1.00 (0.95, 1.04)           ---         0.99 (0.95, 1.04)           ---         0.98 (0.94, 1.04)           ---
  Packs per year (1 U)                          1.03 (1.02, 1.04)    1.02 (1.01, 1.03)  1.02 (1.01, 1.04)    1.02 (1.01, 1.03)  1.02 (1.01, 1.03)    1.02 (1.01, 1.03)
                                                                                                                                                              
  *Smoking status*[b](#t4-fn3){ref-type="fn"}                                                                                                                 
   Former                                       2.54 (1.58, 4.07)    1.55 (0.87, 2.75)  2.55 (1.58, 4.09)    1.48 (0.84, 2.61)  1.80 (1.11, 2.93)    1.08 (0.59, 1.97)
   Active                                       1.48 (0.80, 2.72)    2.18 (1.11, 4.27)  1.65 (0.88, 3.09)    2.44 (1.23, 4.86)  0.75 (0.39, 1.44)    1.25 (0.60, 2.58)
  Hypertension                                  3.03 (1.90, 4.84)    2.17 (1.32, 3.59)  3.01 (1.88, 4.82)    2.12 (1.28, 3.52)  2.76 (1.69, 4.51)    1.83 (1.08, 3.11)
  Diabetes                                      2.87 (1.81, 4.57)    2.26 (1.38, 3.70)  2.43 (1.53, 3.87)    1.85 (1.13, 3.03)  3.52 (2.16, 5.74)    2.91 (1.72, 4.93)
  Dyslipidemia                                  1.45 (0.94, 2.23)    1.54 (0.99, 2.40)  1.53 (0.99, 2.36)    1.53 (0.98, 2.39)  1.09 (0.70, 1.71)    1.06 (0.66, 1.69)
  CV family history                             0.87 (0.52, 1.4)     1.46 (0.86, 2.47)  0.80 (0.48, 1.32)    1.20 (0.72, 2.02)  0.91 (0.54, 1.53)    1.75 (1.01, 3.05)
  Sedentary                                     2.07 (1.27, 3.36)    1.96 (1.17, 3.28)  1.53 (0.95, 2.48)    1.35 (0.81, 2.25)  2.32 (1.39, 3.86)    2.17 (1.25, 3.76)
  CV events                                     3.50 (2.06, 5.96)    2.15 (1.22, 3.78)  4.20 (2.43, 7.27)    2.49 (1.39, 4.45)  3.35 (1.95, 5.74)    2.10 (1.17, 3.77)

Abbreviations: ULLA, ultrasonographic lower limbs atherosclerosis; BMI, body mass index; CV, cardiovascular; OR, odds ratio.

Multivariate models adjusted for age, gender and BMI.

Reference group, never smoked.
